Document:

EX-10.6

 Exhibit 10.6 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
 Amendment No. 1 to License Agreement 

This Amendment No. 1 to License Agreement (this “Amendment No. 1”) is entered into as of this 25th day of October, 2018 (
the “Amendment No. 1 Execution Date”), and shall be deemed effective as of April 1, 2017 (the “Amendment No. 1 Effective Date”), by and between 10X Genomics, Inc. (fka 10X Technologies, Inc.), a Delaware
Corporation, having a place of business at 7068 Koll Center Parkway, Suite 401, Pleasanton, CA 94566 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and
the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727E, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”). Harvard, on the one hand,
and Licensee, on the other, each shall be referred to herein as a “Party” and together as the “Parties”. 
 WHEREAS,
Harvard and Licensee entered into a License Agreement dated as of September 26th, 2013 (the “License Agreement”); and 

WHEREAS, Harvard and Licensee each agree and acknowledge that Licensee is and has been making and selling Licensed Products and
Instrument Products ( as defined below); and 
 WHEREAS, Harvard and Licensee each agree and acknowledge that royalties on sales of
Instrument Products (as defined below) made after the Amendment No. 1 Effective Date should be made at the Rate defined below and are due and owing; and 

WHEREAS, Harvard and Licensee desire to amend the License Agreement in accordance with Section 11.10 thereof, as set forth below;

 NOW, THEREFORE, for good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties agree as
follows: 
  

	I.	 Amendments. 

Section 1.1 of the License Agreement is hereby amended by inserting into the appropriate alphabetical order the following terms: 

“Amendment No. 1 Effective Date” means April 1, 2017. 

“Amendment No. 1 Execution Date” shall mean October 25, 2018. 

“Instrument Products” means (a) Licensed Products that are instruments such as, but not limited to, the GemCode
and Chromium instruments, or (b) any instrument product marketed, sold, used, or otherwise provided by or on behalf of Licensee, its Affiliates or Sublicensees, now or in the future, that is necessary for, or intended for, use in combination or
connection with a Licensed Product for purposes of making, using, or performing a method or product covered within the scope of a Valid Claim. 

  
 1 

 Section 4.3.1 of the License Agreement is hereby amended by deleting it in its entirety
and replacing it with the following: 
 “Rate. Licensee agrees to pay Harvard the following royalty rates on sales of Licensed
Products made after the Amendment No. 1 Effective Date: (i) an amount equal to [***] of all Net Revenues of (a) Licensed Products that are not Instrument Products and (b) Licensed Services, and (ii) an amount equal to
[***]of all Net Revenues of Instrument Products, not to exceed [***] per Instrument Product; provided, however, that no royalty will be due for any Net Revenues of Licensed Products or Licensed Services, the making, selling, use or performance of
which falls solely within the scope of a Valid Claim that has been pending without issuance for more than three (3) years following the date of issuance of the first substantive patent office action considering the patentability of such claim
by the relevant patent office in the country or territory in which such claim is pending (after which time such pending claim shall cease to be a Valid Claim for purposes of Section 4.3.1 of this Agreement unless and until such claim becomes an
issued claim) (each, a “Stale Claim”). For clarity, on a country-by-country basis, if a Licensed Product or Licensed Service is covered by at least one Valid
Claim that is not a Stale Claim, the full royalty rate on such Licensed Product or Licensed Service is due and payable to Harvard.” 
  

	II.	 Except as amended hereby, all other terms of the License Agreement shall remainunchanged and in full force and
effect. 

  

	III.	 This Amendment No. 1 will be governed by, and construed in accordance with, the substantive laws of the
Commonwealth of Massachusetts, without giving effect to any choice or conflict of law provision and may only be amended by a written agreement signed by both Parties referencing this Amendment No. 1. 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be executed by their duly
authorized representatives. 
  

									
	 President and Fellows of Harvard College
	 		 	 10X Technologies, Inc.

					
	By:	 	/s/ Isaac T. Kohlberg	 		 	By:	 	/s/ Ben Hindson
	Name:	 	Isaac T. Kohlberg	 		 	Name:	 	Ben Hindson
		 	Senior Associate Provost	 		 	Title:	 	CSO, President
		 	Chief Technology Development Officer	 		 		 	
		 	Office of Technology Development	 		 		 	
	Title:	 	Harvard University	 		 		 	

  
 3EX-10.7

 Exhibit 10.7 

Certain information has been excluded from this exhibit because it (i) is not material and (ii) would be competitively harmful if publicly
disclosed. 
  

The offer contained herein is subject to Stanford’s conflict of interest review, is subject to HHMI’s review, is valid for a license
which is fully executed by November 4, 2015, and is subject to change without notice thereafter. Stanford is under no obligation to grant a license or any other rights during or beyond the expiration date. 

EXCLUSIVE (EQUITY) AGREEMENT 
 This
Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and EPINOMICS (“Epinomics”), a corporation
having a principal place of business at 1430 O’Brien Dr, Ste D-1, Menlo Park, CA 94025, is effective on the 15th day of October, 2015 (“Effective Date”). 

 

	1.	 BACKGROUND 

Stanford has an assignment of an invention related to mapping chromatin regions, also known as “Fast and efficient chromatin hypersensitivity mapping in
small cell numbers using direct transposition,” invented in the laboratories of Dr. William Greenleaf and Dr. Howard Chang, and described in Stanford Docket S12-404 (the “Invention”).
The Invention was made in the course of research supported by the California Institute of Regenerative Foundation (“CIRM”), The National Institutes of Health (“NIH”), and the Scleroderma Foundation. Dr. Chang was an employee
of The Howard Hughes Medical Institute (“HHMI”) and a Stanford faculty member when the Invention was made. Stanford wants to have the Invention perfected and marketed as soon as possible so that resulting products may be available for
public use and benefit. 
  

	2.	 DEFINITIONS 

  

	2.1	 “Affiliate(s) ” means any person, corporation, or other business entity which controls, is controlled
by, or is under common control with Epinomics; and for this purpose, “control” of a corporation means the direct or indirect ownership of more than fifty percent (50%) of its voting stock, and “control” of any other business
entity means the direct or indirect ownership of greater than a fifty percent (50%) interest in the income of such entity. 

  

	2.2	 “Change of Control” means the following, as applied only to the entirety of that part of
Epinomics’s business that exercises all of the rights granted under this Agreement: 

  

	 	(A)	 acquisition of ownership —directly or indirectly, beneficially or of record—by any person or group
(within the meaning of the Exchange Act and the rules of the SEC or equivalent body under a different jurisdiction) of the capital stock of Epinomics representing more than 45% of either the aggregate ordinary voting power or the aggregate equity
value represented by the issued and outstanding capital stock of Epinomics; and/or 

  
  

PAGE 1 OF 28 

	 	(B)	 the sale of all or substantially all Epinomics’s assets and/or business in one transaction or in a series
of related transactions; 

 provided, however, that in no event shall the sale of equity or other securities for the
primary purpose of financing Epinomics be a Change of Control. 
  

	2.3	 “Exclusive” means that, subject to Articles 3 and 5, Stanford will not grant further licenses under
the Licensed Patents in the specific field in the Licensed Territory. “Exclusivity” has its correlative meaning. 

  

	2.4	 “Exclusive Field of Use” means [***]. The Exclusive Field of Use includes [***].

  

	2.5	 “Fully Diluted Basis” means the total number of shares of Epinomics’s issued and outstanding
common stock, assuming: 

  

	 	(A)	 the conversion of all issued and outstanding securities convertible into common stock; 

 

	 	(B)	 the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and

  

	 	(C)	 the issuance, grant, and exercise of all securities reserved for issuance pursuant to any Epinomics stock or
stock option plan then in effect. 

  

	2.6	 “HHMI Indemnitees” means HHMI and its trustees, officers, employees, and agents.

  

	2.7	 “LDT” means a type of in vitro diagnostic test that is designed, manufactured and used in a single
laboratory. 

  

	2.8	 “Licensed Field of Use” means the Exclusive Field of Use and the Research Field of Use.

  

	2.9	 “Licensed Patent” means Stanford’s PCT application PCT/US2014/38825 filed May 20, 2014, any
foreign patent application corresponding thereto, and any divisional, continuation, or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is
presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. “Licensed Patent” excludes any continuation-in-part (CIP) patent application or patent, which CIP will only be filed upon mutual consent of the parties. 

 

	2.10	 “Licensed Product” means a service, product, or part thereof in the Licensed Field of Use where the
making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent. 

  

	2.11	 “Licensed Territory” means the world. 

  
  

PAGE 2 OF 28 

	2.12	 “Net Sales” means all gross revenue derived and actually received by Epinomics, Affiliates, or
Sublicensees, from the sale, transfer or other disposition of Licensed Product. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are
separately documented and, with respect to (A) through (D) below, actually paid by Epinomics, its Affiliates, or its Sublicensees): 

  

	 	(A)	 import, export, excise and sales taxes, and custom duties; 

 

	 	(B)	 costs of insurance, packing, and transportation from the place of manufacture to the customer’s premises
or point of installation; 

  

	 	(C)	 costs of installation at the place of use; 

 

	 	(D)	 credit or discounts given for returns, allowances, or trades or rejections and other rebates, wholesale
chargebacks and refunds; 

  

	 	(E)	 amounts received for any Licensed Product used in research and/or development or clinical trials provided at
cost or as free samples for promotional use provided that Epinomics does not derive any additional consideration (e.g., cash or otherwise) from the applicable third party from its use of Licensed Product; and 

 

	 	(F)	 amounts received from sales of Licensed Product between Epinomics, its Affiliates, or Sublicensees for the
resale of such Licensed Product to a third party provided that Net Sales will include the amounts received by Affiliates or Sublicensees for such resale. Net Sales will include amounts received by Epinomics for such Affiliate’s or
Sublicensee’s internal use. 

  

	2.13	 “Nonroyalty Sublicensing Consideration” means any consideration received by Epinomics from a
Sublicensee hereunder for a Sublicense but excluding any consideration for: 

  

	 	(A)	 Sublicensee’s Net Sales (Epinomics will pay royalties on Sublicensee’s Net Sales pursuant to
Section 7.8); 

  

	 	(B)	 investments in Epinomics stock; 

 

	 	(C)	 research and development expenses calculated on a fully burdened basis; 

 

	 	(D)	 debt; 

  

	 	(E)	 reimbursement of out-of pocket patent prosecution and maintenance
expenses for Licensed Patents; and 

  

	 	(F)	 the sale of substantially all of the business or assets of Epinomics (or its assignee) whether by merger, sale
of stock or assets or otherwise, provided that Epinomics has completed performance of all conditions in Article 16. 

  

	2.14	 “Research Field of Use” means [***]. 

  
  

PAGE 3 OF 28 

	2.15	 “Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective
trustees, officers, employees, students, agents, faculty, representatives, and volunteers. 

  

	2.16	 “Sublicense” means any agreement between Epinomics and a
non-Affiliate third party that contains a grant to Stanford’s Licensed Patents regardless of the name given to the agreement by the parties; however, an agreement to make, have made, use or sell Licensed
Products on behalf of Epinomics is not considered a Sublicense. 

  

	2.17	 “Sublicensee” means any third party grantee of a Sublicense. 

 

	3.	 GRANT 

  

	3.1	 Grant. Subject to the terms and conditions of this Agreement, Stanford grants Epinomics a license under
the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell, have sold, and sell Licensed Product in the Licensed Territory. 

 

	3.2	 Exclusivity. 

  

	 	(A)	 Exclusivity in Exclusive Field of Use. The license in Section 3.1 is Exclusive, including the right
to sublicense under Article 4, in the Exclusive Field of Use beginning on the Effective Date and ending on the later of: 

  

	 	(1)	 December 31, 2025 (the “Initial Exclusive Term”); or 

 

	 	(2)	 The expiration of the Extended Exclusive Term. Section 3.2(A)(1) above notwithstanding, Epinomics may
extend the Exclusive term of the license in the Exclusive Field of Use for additional one-year terms (the “Extended Exclusive Term” and collectively with the Initial Exclusive Term, the
“Exclusive Term”) in the event that Net Sales of Licensed Products equal or exceed the following minimums: 

  

	 	(a)	 $6 million in the year before the Exclusivity would have otherwise ended pursuant to Section 3.2(A)(1);

  

	 	    	 $8 million in each of the next 2 years (i.e. 1st and 2nd years after the Exclusivity would have otherwise ended
pursuant to Section 3.2(A)(1)); 

  

	 	    	 $12 million each in each of the next 2 years (i.e. 3rd and 4th years after the Exclusivity would have otherwise
ended pursuant to Section 3.2(A)(1)); and 

  

	 	    	 $15 million each year thereafter. 

 

	 	(b)	 In order to extend the Exclusivity in the Exclusive Field of Use under this Section 3.2(A), Epinomics must
confirm in writing to Stanford that it has achieved the applicable annual minimum Net Sales in accordance with this Section 3.2(A). For example: If Epinomics confirmed in writing that its sales of Licensed Products in the year ending December
31, 2025 exceeded $6 million, then the Extended Exclusive Term would extend to December 31, 2026. If the following year Epinomics confirmed in writing that its sales of Licensed Products in the year ending December 31, 2026 exceeded $8 million, the
Extended Exclusive Term would extend to December 31, 2027. 

  

	 	(B)	 Exclusivity in Research Field of Use. The license in Section 3.1 is Exclusive, including the right
to sublicense under Article 4, in the Research Field of Use beginning on the Effective Date and ending [***] (the “Research Field Exclusivity Period”). Stanford may reduce the Research Field Exclusivity Period by converting the license in
the Research Field of Use to nonexclusive pursuant to Section 6.1. 

  
  

PAGE 4 OF 28 

	3.3	 Nonexclusivity. 

 

	 	(A)	 After the expiration of the Exclusive Term (for clarity, in the event there is no extension of the Exclusive
term in accordance with Section 3.2(A)(1) above, upon expiration of the Initial Exclusive Term, or in the event there is an extension of the Exclusive term in accordance with Section 3.2(A)(1) above upon the expiration of the applicable
Extended Exclusive Term), the license will be nonexclusive in the Exclusive Field of Use until the date of expiration of the last Licensed Patent to expire. 

  

	 	(B)	 After the expiration of the Research Field Exclusivity Period, the license is nonexclusive in the Research
Field of Use until the date of expiration of the last Licensed Patent to expire. 

  

	3.4	 Retained Rights. Stanford retains the right, on behalf of itself, Stanford Hospital and Clinics, and all
other non-profit research institutions, to practice the Licensed Patent for any non-profit purpose, including sponsored research and collaborations. Epinomics agrees
that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right to publish any information included in a Licensed
Patent. 

  

	3.5	 HHMI Research License. Epinomics acknowledges that it has been informed that the Licensed Patent was
developed, at least in part, by employees of HHMI and that HHMI has a paid-up, non-exclusive, irrevocable license to use the Licensed Patent for HHMIs research purposes,
but with no right to assign or sublicense (the “HHMI License”). This Agreement is explicitly made subject to the HHMI License. 

  

	3.6	 Specific Exclusion. Stanford does not: 

 

	 	(A)	 grant to Epinomics any other licenses, implied or otherwise, to any patents or other rights of Stanford other
than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent; 

 

	 	(B)	 commit to Epinomics to bring suit against third parties for infringement, except as described in Article 14;
and 

  

	 	(C)	 agree to furnish to Epinomics any technology or technological information, or to provide Epinomics with any
assistance. 

  

	4.	 SUBLICENSING 

  

	4.1	 Permitted Sublicensing. 

 

	 	(A)	 Only if Epinomics is developing or commercially distributing Licensed Products, directly or through its
Sublicensees or Affiliates, Epinomics may grant Sublicenses in the Exclusive Field of Use only during the Exclusive Term or in the Research Field of Use only during the Research Field Exclusivity Period. 

  
  

PAGE 5 OF 28 

	 	(B)	 Sublicenses with any exclusivity must include diligence requirements commensurate with the diligence
requirements of Appendix A. Stanford agrees that Epinomics may apportion without discrimination between Epinomics and Stanford patents a commercially reasonable percentage of sublicensing payments made to Stanford pursuant to Section 4.6,
provided however that Epinomics provides Stanford with the proposed apportionment and justification prior to Epinomics’s payment pursuant to Section 8.1. Stanford and Epinomics agree to meet to discuss such proposed apportionment if in
Stanford’s opinion the apportionment does not reasonably reflect the value of the Licensed Patents. 

  

	4.2	 Required Sublicensing. 

 

	 	(A)	 If Epinomics, directly or through its Affiliates or Sublicensee(s), is unable or unwilling to serve or develop
a potential market or market territory for which there is a company willing to be a Sublicensee and has adequate resources and a bona fide, detailed proposal to develop a Licensed Product for such potential market or market territory, Epinomics
will, at Stanford’s request, and at Epinomics’s election: 

  

	 	(1)	 negotiate in good faith a Sublicense with any such company; or 

 

	 	(2)	 provide Stanford with a detailed proposal describing how Epinomics will develop a Licensed Product for such
potential market or market territory and the parties discuss in good faith additional diligence for Appendix A; or 

  

	 	(3)	 demonstrate in a written document to Stanford that such company’s proposed development is competitive with
Epinomics’s current or planned Licensed Products. 

  

	 	(B)	 Stanford would like licensees to address unmet needs, such as those of neglected patient populations or
geographic areas, giving particular attention to improved therapeutics, diagnostics and agricultural technologies for the developing world. 

  

	4.3	 Sublicense Requirements. Any Sublicense: 

 

	 	(A)	 is subject to this Agreement; 

 

	 	(B)	 will reflect that any Sublicensee will not further sublicense, except with Stanford’s prior written
consent; 

  

	 	(C)	 will prohibit Sublicensee from paying royalties to an escrow or other similar account; 

 

	 	(D)	 will expressly include the provisions of Articles 8, 9, 10, and 13, and Section 20.5 for the benefit of
Stanford and/or HHMI, as the case may be; and 

  
  

PAGE 6 OF 28 

	 	(E)	 will include the provisions of Section 4.4 and require the transfer of all the Sublicensee’s
obligations to Epinomics that are within the scope of Epinomics’ obligations to Stanford, including the payment of royalties specified in this Agreement, to Stanford or its designee, if this Agreement is terminated. If the Sublicensee is a spin-out from Epinomics, Epinomics must guarantee the Sublicensee’s performance with respect to the payment of Stanford’s share of Sublicense royalties. 

 

	4.4	 Litigation by Sublicensee. Any Sublicense must include the following clauses: 

 

	 	(A)	 In the event Sublicensee brings an action seeking to invalidate any Licensed Patent: 

 

	 	(1)	 Sublicensee will double the payment paid to Epinomics during the pendency of such action for Net Sales.
Moreover, should the outcome of such action determine that any claim of a patent challenged by the Sublicensee is both valid and infringed by a Licensed Product, Sublicensee will pay triple the payment paid under the original Sublicense for Net
Sales; 

  

	 	(2)	 Sublicensee will have no right to recoup any royalties paid before or during the period of such challenge;

  

	 	(3)	 any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa
Clara County, and the parties agree not to challenge personal jurisdiction in that forum; and 

  

	 	(4)	 Sublicensee shall not pay royalties into any escrow or other similar account. 

 

	 	(B)	 Sublicensee will provide written notice to Stanford at least three months prior to bringing an action seeking
to invalidate a Licensed Patent. Sublicensee will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. 

 

	4.5	 Copy of Sublicenses and Sublicensee Royalty Reports. Epinomics will submit to Stanford a copy of each
Sublicense, any subsequent amendments and all copies of Sublicensees’ royalty reports (each of which may be reasonably redacted to exclude confidential information that is not necessary for Stanford to enforce its payment rights or to confirm
compliance under this Agreement). Beginning with the first Sublicense, the Chief Financial Officer or equivalent will certify annually regarding the name and number of Sublicensees. 

 

	4.6	 Sharing of Sublicensing Income. Epinomics will pay to Stanford a portion of all Nonroyalty Sublicensing
Consideration for the Sublicense of Licensed Patents, as provided below: 

  

	 	[***]	 

  

	4.7	 Royalty-Free Sublicenses. If Epinomics pays all royalties due Stanford from a Sublicensee’s
Net Sales, Epinomics may grant that Sublicensee a royalty-free or non-cash: 

  

	 	(A)	 Sublicense or 

  

	 	(B)	 cross-license. 

  
  

PAGE 7 OF 28 

	5.	 GOVERNMENT RIGHTS 

This Agreement is subject to Title 35 Sections 200-204 of the United States Code. Among other things, these provisions
provide the United States Government with nonexclusive rights in the Licensed Patent. They also impose the obligation that Licensed Product sold or produced in the United States be “manufactured substantially in the United States.” In
addition, due to CIRM funding, this Agreement is subject to Title 17, California Code of Regulations and the provisions of section 100607 under Title 17 place requirements on Epinomics for access to Licensed Product in California. Epinomics will
ensure all obligations of these provisions are met. 
  

	6.	 DILIGENCE 

  

	6.1	 Milestones. Because the Invention is not yet commercially viable as of the Effective Date, Epinomics
will itself or through its Affiliates and/or Sublicensees, use commercially reasonable efforts to develop, manufacture, and sell Licensed Product and will use commercially reasonable efforts to develop markets for Licensed Product. In addition,
Epinomics will use commercially reasonable efforts to meet the milestones shown in Appendix A, and notify Stanford in writing as each milestone is met Stanford agrees to grant reasonable extensions to the target dates of any applicable milestone and
the subsequent milestones (without payment) if Epinomics’s failure to meet the applicable milestones is due to delays which are out of the reasonable control of Epinomics (e.g., changes to the regulatory pathways, delays in regulatory review,
adverse events during clinical trials and the like), provided that Stanford shall not be obligated to grant such extension for more than 1 year in aggregate and any additional request for extension will be subject to discussion by the parties. If
Epinomics fails to meet Milestone 6 set forth on Appendix A, Stanford may, in its sole discretion, convert the license in the Research Field of Use to nonexclusive. 

 

	6.2	 Progress Report. By March 1 of each year, Epinomics will submit a written annual report to Stanford
covering the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and CIRM, and for Stanford to ascertain progress by Epinomics toward meeting this
Agreement’s diligence requirements. Each report will describe, where relevant: Epinomics’s progress toward commercialization of Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Product, and significant corporate transactions involving
Licensed Product. Epinomics will specifically describe how each Licensed Product is related to each Licensed Patent. 

  

	6.3	 Clinical Trial Notice. Epinomics will notify the Stanford University Office of Technology Licensing
prior to commencing any clinical trials at Stanford. 

  
  

PAGE 8 OF 28 

	7.	 ROYALTIES 

  

	7.1	 Issue Royalty. Epinomics will pay to Stanford a noncreditable, nonrefundable license issue royalty of
[***] upon signing this Agreement. 

  

	7.2	 Equity Interest. As further consideration, Epinomics will grant to Stanford [***]shares of common stock
in Epinomics (the “Initial Equity”). When issued, those shares will represent [***]in Epinomics on a Fully Diluted Basis. The shares are valued as set forth in the letter from Epinomics to Stanford attached as Appendix C. Epinomics
agrees to provide Stanford with the capitalization table upon which the above calculation is made and to provide letter stating the value of shares. Epinomics will issue [***]of all of the Equity pursuant to this Section 7.2 and
Section 7.3 directly to and in the name of the inventors listed below allocated as stated below: 

 [***] 

Notwithstanding the foregoing, if any of the individual inventors listed above do not wish to receive such shares, Epinomics will issue those
shares to and in the name of Stanford. 
  

	7.3	 Anti-Dilution Protection. Epinomics will issue Stanford and the inventors listed in Section 7.2,
without further consideration, any additional shares of common stock of Epinomics to ensure that the number of shares of common stock issued to Stanford and the inventors pursuant to Section 7.2 and this Section 7.3 (the “Dilution
Shares” together with the Initial Grant, the “Equity”) does not represent less than [***] of the shares issued and outstanding on a Fully-Diluted Basis at any time through the completion of issuance of all shares to
be issued in connection with the First Round of bona fide equity investment in Epinomics from a single or group of investors which is both (i) with total proceeds to Epinomics of at least [***]and (ii) at a price per share which, when
multiplied by Epinomics’s capitalization on a Fully Diluted Basis, implies a post-financing equity valuation of Epinomics of at least [***]. A “First Round” is a bona fide round of equity, warrant, option or convertible equity
investment which includes all the tranches prior to the completion of the financing. This right will expire upon the issuance of all shares to be issued in connection with such First Round, but will apply to all shares to be issued in or in
connection with such First Round. 

  

	7.4	 Purchase Right. 

 

	 	(A)	 Stanford shall have the right, but not the obligation, to purchase for cash up to its Share of the securities
issued in any Qualifying Offering on the terms, and subject to the conditions, set forth in this Section 7.4 and Section 7.5 (the “Purchase Right”). For purposes of this Section 7.4 and Section 7.5:

  

	 	(1)	 “Adjustment Event” means the final closing of the first Threshold Qualifying Offering occurring after
the date of this Agreement. 

  

	 	(2)	 “Board of Directors” means (i) if Epinomics is organized as a corporation, its board of
directors, and (ii) if Epinomics is organized as a limited liability company, Epinomics manager(s) or member(s) or both that have the power to direct the principal management and activities of Epinomics, whether through ownership of voting
securities, by agreement, or otherwise. 

  
  

PAGE 9 OF 28 

	 	(3)	 “Qualifying Offering” means a private offering of Epinomics’s equity securities (or securities
convertible into or exercisable for Epinomics’s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing on or after the date of this Agreement and which includes investment by one or more venture
capital, professional angel, corporate or other similar institutional investors other than Stanford. For the avoidance of doubt, if Epinomics is a limited liability company, then “equity securities” means limited liability company
interests in Epinomics. 

  

	 	(4)	 “Share” means: 

 

	 	(i)	 [***] with respect to any Qualifying Offering having a closing on or before the date of an Adjustment Event; or

  

	 	(ii)	 with respect to any Qualifying Offering having a closing after an Adjustment Event, but before a Termination
Event, the percentage necessary for Stanford to maintain its pro rata ownership interest in Epinomics on a Fully-Diluted Basis. 

  

	 	(5)	 “Threshold Qualifying Offering” means any Qualifying Offering which either (i) is at least [***]
in size or (ii) involves the sale to outside investors of at least [***] of the equity securities outstanding after such round on a Fully-Diluted Basis. 

  

	 	(6)	 The parties shall construe the term “Fully-Diluted Basis” mutatis mutandis in the case where
Epinomics is organized as a limited liability company. 

  

	 	(B)	 The Purchase Right shall terminate upon the earliest to occur of the following (each a “Termination
Event”): 

  

	 	(1)	 Stanford’s execution of an investor rights agreement or similar agreement (each a “Rights
Agreement”) in connection with a Threshold Qualifying Offering so long the Rights Agreement satisfies the terms of this Section 7.4 and Section 7.5 below; 

 

	 	(2)	 Stanford purchases less than its entire Share of a Qualifying Offering; 

 

	 	(3)	 Stanford fails to give an election notice within the Notice Period for a Qualifying Offering which has its
final closing within 90 days of the date such notice is received by Stanford and which is closed on terms that are the same or less favorable to the investors as the terms stated in Epinomics’s notice to Stanford; 

 

	 	(4)	 The closing of a firm commitment underwritten public offering of Epinomics’s common stock; or

  

	 	(5)	 The closing of the sale of all or substantially all of Epinomics’s assets to a company publicly traded on
one of the major recognized exchanges. 

  
  

PAGE 10 OF 28 

	 	(C)	 The Purchase Right shall not apply to the issuance of securities: (i) to employees, individuals who are
members of Epinomics’s Board of Directors as of the time of issuance, and service providers to Epinomics pursuant to a plan approved by Epinomics’s Board of Directors; or (ii) as additional consideration in lending or leasing
transactions; or (iii) to an entity pursuant to an arrangement that Epinomics’s Board of Directors determines in good faith is a strategic partnership or similar arrangement of Epinomics (i.e., an arrangement in which the entity’s
purchase of securities is not primarily for the purpose of financing Epinomics); or (iv) to owners of another entity in connection with the acquisition of that entity by Epinomics. 

 

	 	(D)	 For the avoidance of doubt: (i) any securities Stanford may acquire or have the right to acquire under
Section 7.2 or 7.3 shall not reduce the number of securities Stanford may purchase under this Section 7.4 or under any applicable Rights Agreement; and (ii) Stanford shall not be obligated to purchase under this Section 7.4 any
Epinomics securities it has the right to acquire under Section 7.2 or 7.3 above. 

  

	7.5	 Rights Agreements; Information Rights; Notice; Elections. 

 

	 	(A)	 Epinomics shall ensure that each Rights Agreement executed by Stanford in connection with a Qualifying Offering
will grant to Stanford the same rights as all other investors who are parties to that Rights Agreement. In particular, Epinomics shall ensure that each such Rights Agreement will grant to Stanford the same right to purchase additional securities in
future offerings, the same information rights, and the same registration rights as are granted to other parties thereto, including all such rights granted to any investor designated as a “Major Investor” or other similar designation, even
if Stanford is not so designated. 

  

	 	(B)	 Notwithstanding any terms to the contrary contained in any applicable Rights Agreement: 

 

	 	(1)	 Stanford shall not have any representation on the Board of Directors or rights to attend meetings of the Board
of Directors; 

  

	 	(2)	 In connection with all Qualifying Offerings, Epinomics shall give Stanford notice of the terms of the offering,
including: (i) the names of the investors, the allocation of equity securities among them and the total amounts to be invested by each of them in such offering; (ii) pre- and post- (projected)
financing capitalization table; (iii) investor presentation (if available); (iv) an introduction to the lead investor in such offering for the purpose of discussing the lead investor’s due diligence process; and (v) such other
documents and information as Stanford may reasonably request for the purpose of making an investment decision or verifying the amount of equity securities it is entitled to purchase in such offering; and 

  
  

PAGE 11 OF 28 

	 	(3)	 Stanford may elect to exercise its Purchase Right, in whole or in part, by notice given to Epinomics within 15
Stanford business days (i.e., days other than Saturdays, Sundays, and holidays or other days on which Stanford is officially closed) after receipt of Epinomics’s notice (“Notice Period”). 

 

	 	(C)	 If Stanford has no information rights under a Rights Agreement and to the extent that such information has been
prepared by Epinomics for other purposes, so long as Stanford holds Epinomics securities, Epinomics shall furnish to Stanford, upon request and as promptly as reasonably practicable, Epinomics’s annual consolidated financial statements and
annual operating plan, including an annual report of the holders of Epinomics’s securities, and such other information as Stanford may reasonably request from time to time for the purpose of valuing its interest in Epinomics.

  

	 	(D)	 Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement
that refers or relates to any of Section 7.4 above or this Section 7.5 shall be copied concurrently to pvfnotices@stanford.edu: provided, however, that delivery of the copy will not by itself constitute notice for any purpose
under this Agreement. 

  

	7.6	 License Maintenance Fee. 

 

	 	(A)	 Beginning October 15, 2016 and each anniversary thereafter, Epinomics will pay Stanford a yearly license
maintenance fee of: 

 [***] 
  

	 	(B)	 Yearly maintenance payments are nonrefundable, but they are creditable each year as described in
Section 7.12. 

  

	7.7	 Milestone Payments. Epinomics will pay Stanford the following milestone payments: 

[***] 
 It is further agreed and
notwithstanding the above provisions of this Section 7.7, in the event Epinomics receives a milestone payment from a Sublicensee under a Sublicense and the milestone event giving rise to such milestone payment also triggers a payment obligation
on the part of Epinomics under this Section 7.7, Epinomics shall be obligated to pay Stanford only a single payment, such payment to be the higher of the applicable milestone payment set forth in this Section 7.7and the payment owing to
Stanford under Section 4.6 as applicable, with respect to such milestone payment from such Sublicensee 
  

	7.8	 Earned Royalty. Epinomics will pay Stanford earned royalties (Y%) on Net Sales as follows:

 [***] 

  
  

PAGE 12 OF 28 

	7.9	 Combination Product. In the event that a Licensed Product is sold in combination with another product,
component or service for which no royalty would be due hereunder if sold separately (together as a combination, “Combination Product”), Net Sales from such Combination Product sales for purposes of calculating the amounts due under this
Article 7 shall be calculated by multiplying the Net Sales of the Combination Product by the fraction (A-B)/A, where A is the market value of the Combination Product as determined by its separately listed sale
price and B is the market value of the other products, components or services as determined by their separately listed sale price (if any). In the event that the other product/s, component/s or service/s are not separately listed, the average of the
separately listed sale price during the preceding calendar quarter of the other product(s), component(s) or service(s) will be used; provided that if separate sales of the other product/s, component/s or service/s were not made during the preceding
calendar quarter, then the Net Sales on the Combination Product shall be reasonably allocated between such Licensed Product, and such other product/s, component/s or service/s based upon their relative importance and proprietary protection as
mutually agreed upon by Stanford and Epinomics. 

  

	7.10	 Single Royalty. No more than one royalty payment under this Agreement shall be due to Stanford with
respect to a sale of a particular Licensed Product. Multiple royalties shall not be payable because any Licensed Product, or its manufacture, sale or use, is covered by more than one claim within the Licensed Patents. 

 

	7.11	 Earned Royalty if Epinomics Challenges the Patent. Notwithstanding the above, should Epinomics bring an
action seeking to invalidate any Licensed Patent, Epinomics will pay royalties to Stanford at the rate of 2 x Y percent (2xY%) of the Net Sales of all Licensed Products sold during the pendency of such action. Moreover, should the outcome of such
action determine that any claim of a patent challenged by Epinomics is both valid and infringed by a Licensed Product, Epinomics will pay royalties at the rate of 3 x Y percent (3xY%) of the Net Sales of all Licensed Products sold after such
determination. 

  

	7.12	 Creditable Payments. The license maintenance fee for a year may be offset against earned royalty
payments due on Net Sales occurring in that year. 

 For example: 

[***] 
  

	7.13	 Obligation to Pay Royalties. An earned royalty is due Stanford under this Agreement for each Licensed
Product sold, transferred, or otherwise disposed under the licenses granted. For convenience’s sake, the amount of that royalty is calculated using Net Sales. During the term of this Agreement an earned royalty is due Stanford pursuant to
Section 7.8 on a country-by-country basis until the date of expiration of the last Licensed Patent to expire within such country of manufacture, use, import, or
sale covering such Licensed Product. Thereafter, no further royalties shall be due with respect to such Licensed Product in such country. Nonetheless, if certain Licensed Products are made, used, imported, or offered for sale before the date this
Agreement terminates, and those Licensed Products are sold after the termination date, Epinomics will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products; [***]. 

  
  

PAGE 13 OF 28 

	7.14	 No Escrow. Epinomics shall not pay royalties into any escrow or other similar account.

  

	7.15	 Currency. Epinomics will calculate the royalty on sales in currencies other than U.S. Dollars using the
appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. Epinomics will make royalty payments to Stanford in U.S. Dollars. 

 

	7.16	 Non-U.S. Taxes. Epinomics will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. 

  

	7.17	 Interest. Any payments not made when due will bear interest at the lower of (a) the Prime Rate
published in the Wall Street Journal plus 200 basis points or (b) the maximum rate permitted by law. 

  

	8.	 ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING 

 

	8.1	 Quarterly Earned Royalty Payment and Report. Beginning with the first sale of a Licensed Product by
Epinomics or a Sublicensee, Epinomics will submit to Stanford a written report (even if there are no sales) and an earned royalty payment within sixty (60) days after the end of each calendar quarter. This report will be in the form of Appendix
B and will state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned
royalties are calculated. With each report Epinomics will include any earned royalty payment due Stanford for the completed calendar quarter (as calculated under Section 7.8). 

 

	8.2	 No Refund. In the event that a validity or non-infringement
challenge of a Licensed Patent brought by Epinomics is successful, Epinomics will have no right to recoup any royalties paid before or during the period challenge. 

 

	8.3	 Termination Report. Epinomics will pay to Stanford all applicable royalties and submit to Stanford a
written report within 90 days after the license terminates. Epinomics will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been
sold. 

  

	8.4	 Accounting. Epinomics will maintain records showing manufacture, importation, sale, and use of a
Licensed Product for 7 years from the date of sale of that Licensed Product. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and
related information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement. 

  

	8.5	 Audit by Stanford. Upon reasonable advance notice, Epinomics will allow Stanford or its designee once
per year to examine Epinomics’s records maintained in accordance with Section 8.4 as reasonably necessary to verify payments made by Epinomics under this Agreement. 

  
  

PAGE 14 OF 28 

	8.6	 Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals
an underreporting of earned royalties due Stanford of 5% or more for the period being audited, Epinomics will pay the audit costs. 

  

	8.7	 Self-audit. Epinomics will conduct an independent audit of sales and royalties at least every 2 years if
annual Net Sales of Licensed Product are over $5,000,000. The audit will address, at a minimum, the amount of gross sales by or on behalf of Epinomics during the audit period, the amount of funds owed to Stanford under this Agreement, and whether
the amount owed has been paid to Stanford and is reflected in the records of Epinomics. Epinomics will submit the auditor’s report promptly to Stanford upon completion. Epinomics will pay for the entire cost of the audit. 

 

	9.	 EXCLUSIONS AND NEGATION OF WARRANTIES 

 

	9.1	 Negation of Warranties. Stanford provides Epinomics the rights granted in this Agreement AS IS and WITH
ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: 

 

	 	(A)	 of merchantability, of fitness for a particular purpose; 

 

	 	(B)	 of non-infringement; or 

 

	 	(C)	 arising out of any course of dealing. 

 

	9.2	 No Representation of Licensed Patent. Epinomics also acknowledges that Stanford does not represent or
warrant: 

  

	 	(A)	 the validity or scope of any Licensed Patent; or 

 

	 	(B)	 that the exploitation of Licensed Patent will be successful. 

 

	10.	 INDEMNITY 

  

	10.1	 Indemnification. 

 

	 	(A)	 Epinomics will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind
arising out of or related to the exercise of any rights granted Epinomics under this Agreement or the breach of this Agreement by Epinomics. Stanford agrees to inform Epinomics promptly in writing of any claim or threatened claim that may give rise
to an obligation of indemnity under this Agreement of which Stanford becomes aware. Epinomics’ obligations to a Stanford Indemnitee under this section may be relieved only to the extent that Epinomics can demonstrate material prejudice caused
by (1) Stanford’s failure to provide adequate or timely notice of the claim; (2) the Stanford Indemnitee making an admission 

  
  

PAGE 15 OF 28 

	 	
regarding such claim without the prior written consent of Epinomics, which consent shall not be unreasonably withheld; and (3) the gross negligence or willful misconduct of the Stanford
Indemnitee. Stanford will provide Epinomics with the exclusive control of the defense or settlement of each claim, provided that Epinomics must do so in a manner that does not adversely affect Stanford’s interests and it must obtain
Stanford’s prior consent to any settlement. 

  

	 	(B)	 HHMI Indemnitees will be indemnified, defended by counsel acceptable to HHMI, and held harmless by Epinomics
from and against any claim, liability, cost, expense, damage, deficiency, loss, or obligation, of any kind or nature (including, without limitation, reasonable attorneys’ fees and other costs and expenses of defense) (collectively,
“Claims”), based upon, arising out of, or otherwise relating to this Agreement, including without limitation any cause of action relating to product liability. The previous sentence will not apply to any Claim that is determined with
finality by a court of competent jurisdiction to result solely from the gross negligence or willful misconduct of an HHMI Indemnitee. Notwithstanding any other provision of this Agreement, Epinomics’s obligation to defend, indemnify and hold
harmless the HHMI Indemnitees under this paragraph will not be subject to any limitation or exclusion of liability or damages or otherwise limited in any way. 

 

	10.2	 No Indirect Liability. Neither party shall be liable for any special, consequential, lost profit,
expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise; provided however that the foregoing
shall not apply: 

  

	 	(A)	 to any claim for which Epinomics is obligated to indemnify any HHMI Indemnitee under Section 10.1(B); and

  

	 	(B)	 to any right of action for infringement, contributory infringement or inducement of infringement Stanford may
have under any applicable law. 

 Stanford shall not have any responsibilities or liabilities whatsoever with respect to
Licensed Product(s). 
  

	10.3	 Workers’ Compensation. Epinomics will comply with all statutory workers’ compensation and
employers’ liability requirements for activities performed under this Agreement. 

  

	10.4	 Insurance. During the term of this Agreement, Epinomics will maintain Comprehensive General Liability
Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of Epinomics and its Affiliates and will require its Sublicensees to carry such insurance to cover the activities of
such Sublicensees. The insurance will provide minimum limits of liability of $5,000,000 and will include all Stanford Indemnitees and HHMI Indemnitees as additional insureds. Insurance must cover claims incurred, discovered, manifested, or made
during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as 

  
  

PAGE 16 OF 28 

 
rated by A.M. Best. Within 15 days of the Effective Date of this Agreement, Epinomics will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements.
Epinomics will provide to Stanford 30 days prior written notice of cancellation or material change to this insurance coverage. Epinomics will advise Stanford in writing that it maintains excess liability coverage (following form) over primary
insurance for at least the minimum limits set forth above. All insurance of Epinomics will be primary coverage; insurance of Stanford Indemnitees and HHMI Indemnitees will be excess and noncontributory. 

 

	11.	 EXPORT 

Epinomics and its Affiliates and Sublicensees shall comply with all United States laws and regulations controlling the export of licensed commodities and
technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material or supply but does not include information; and “technical data” means tangible or intangible technical information that is
subject to U.S. export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export
Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions regulations administered
by the U.S. Department of the Treasury (31 CFR 500-600). 
 Among other things, these laws and regulations prohibit
or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Epinomics hereby gives written assurance that it will comply with, and will cause its Affiliates and
Sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its Affiliates or Sublicensees, and that it will indemnify, defend and
hold Stanford harmless for the consequences of any such violation. 
  

	12.	 MARKING 

Before any Licensed Patent issues, Epinomics will mark Licensed Product with the words “Patent Pending.” Otherwise, Epinomics will mark Licensed
Product with the number of any issued Licensed Patent. 
  

	13.	 NAMES AND MARKS 

Epinomics will not use (i) Stanford’s or HHMI’s name or other trademarks, (ii) the name or trademarks of any organization related to
Stanford or HHMI, or (iii) the name of any Stanford or HHMI faculty member, employee, student or volunteer without the prior written consent of the party (Stanford, or HHMI, or the applicable individual, as the case may be) whose name or
trademark is being used. Permission may be withheld at Stanford’s or HHMI’s sole discretion. This prohibition includes, but is not limited to, use in press releases, advertising, marketing materials, other promotional materials,
presentations, case studies, reports, websites, application or software interfaces, and other electronic media. Notwithstanding anything to the contrary herein, Epinomics may without prior permission, reasonably utilize Stanford’s name or names
of Stanford employees in statements of fact (provided such statements do not imply endorsement of Epinomics’s products or services) in legal proceedings, patent filings, and regulatory filings. 

  
  

PAGE 17 OF 28 

	14.	 PROSECUTION AND PROTECTION OF PATENTS 

 

	14.1	 Patent Prosecution. 

 

	 	(A)	 Stanford will be responsible for and will keep Epinomics reasonably informed as to the preparing, filing, and
prosecuting and maintaining all Licensed Patents. Epinomics will receive copies of all documentation and substantive actions pertaining to the filing, prosecution, and maintenance of Licensed Patents. Epinomics will have reasonable opportunities to
participate in decision making and Stanford will give Epinomics a reasonable opportunity to comment on material documents filed with any patent office with respect to the Licensed Patents and will consider in good faith and use reasonable efforts to
incorporate Epinomics’s comments. 

  

	 	(B)	 Stanford will, at Epinomics’s request, file, prosecute and maintain Licensed Patents in foreign countries,
if available. 

  

	 	(C)	 In the event Epinomics decides that it no longer intends to pay for prosecution or maintenance of any
particular patent application or patent within the Licensed Patents, Epinomics shall provide Stanford three (3) months’ notice before the patent office deadline. Stanford may in its discretion continue to prosecute and maintain such patent
application or patent at its expense. Pursuant to Section15.1(B), such patent application or patent shall cease to be within the Licensed Patents for purposes of this Agreement. 

 

	14.2	 Patent Costs. Within 30 days after receiving a statement from Stanford, Epinomics will reimburse
Stanford: 

  

	 	(A)	 $1771.90 to offset Licensed Patent’s patenting expenses, including any interference or reexamination
matters, reasonably incurred by Stanford before the Effective Date; and 

  

	 	(B)	 for all out-of-pocket Licensed
Patent’s patenting expenses, including any interference or reexamination matters, incurred by Stanford after the Effective Date. In all instances, Stanford will pay the fees prescribed for large entities to the United States Patent and
Trademark Office. 

  

	14.3	 Infringement Procedure. Each party will promptly notify the other party if it believes a third party
infringes a Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed Patent. During the Exclusive Term of this Agreement and if Epinomics is developing Licensed Product, Epinomics may have the right to
institute a suit in the Exclusive Field of Use against or defend any declaratory judgment action initiated by this third party as provided in Section 14.4 through and including Section 14.9. 

  
  

PAGE 18 OF 28 

	14.4	 Stanford Suit. If neither Section 14.5 or 14.6 apply, or if Epinomics does not initiate an
enforcement action within 120 days of a request by Stanford to do so or Epinomics does not elect to control a declaratory judgment action within 90 days of receiving notice that such action has been filed, Stanford may institute suit and may name
Epinomics as a party for standing purposes. If Stanford decides to institute suit, it will notify Epinomics in writing. If Epinomics does not notify Stanford in writing that it desires to jointly prosecute the suit within 15 days after the date of
the notice, Epinomics will assign and hereby does assign to Stanford all rights, causes of action, and damages resulting from the alleged infringement. Stanford will bear the entire cost of the litigation and will retain the entire amount of any
recovery or settlement. 

  

	14.5	 Joint Suit. If Stanford and Epinomics so agree, they may institute suit or defend the declaratory
judgment action jointly. If so, they will: 

  

	 	(A)	 prosecute the suit in both their names; 

 

	 	(B)	 bear the out-of-pocket costs
equally; 

  

	 	(C)	 share any recovery or settlement equally; and 

 

	 	(D)	 agree how they will exercise control over the action. 

 

	14.6	 Epinomics Suit. During the Exclusive Term in the Exclusive Field of Use and during the Research Field
Exclusivity Period in the Research Field of Use, Epinomics has the first right to institute suit, or defend any action for declaratory judgment relating to the Licensed Patent in that specific field and to prosecute a suit or defend any declaratory
judgment action so long as it conforms with the requirements of this Section 14.6 and Epinomics, its Affiliates or its Sublicensee is using commercially reasonable efforts to develop and/or manufacture and sell Licensed Product. If Epinomics
decides to institute suit or defend any action, it will notify Stanford in writing and give Stanford the opportunity to agree to jointly initiate suit or defend the action as provided in Section 14.5. If Stanford declines to join, Epinomics
will diligently pursue the suit and Epinomics will bear the entire cost of the litigation, including expenses and counsel fees incurred by Stanford. Epinomics will keep Stanford reasonably apprised of all developments in the suit, and will seek
Stanford’s input and approval on any substantive submissions or positions taken in the litigation regarding the scope, validity and enforceability of the Licensed Patent. Epinomics will not prosecute, settle or otherwise compromise any such
suit in a manner that adversely affects Stanford’s interests without Stanford’s prior written consent. Stanford may be named as a party only if 

  

	 	(A)	 Epinomics’s and Stanford’s respective counsel recommend that such action is necessary in their
reasonable opinion to achieve standing, or a court has required or will require such joinder to pursue the action; 

  

	 	(B)	 Stanford is not the first named party in the action; and 

 

	 	(C)	 the pleadings and any public statements about the action state that Epinomics is pursuing the action and that
Epinomics has the right to join Stanford as a party. 

  
  

PAGE 19 OF 28 

	14.7	 Cooperation. After the expiration of the Research Field Exclusivity Period, in the event of an
infringement or declaratory action relating to the Licensed Patent in the Research Field of Use, Epinomics and Stanford will meet to discuss next steps to take about the known or suspected infringement. Such steps will also consider the rights and
interests of any other parties who may have license rights to the Licensed Patents. 

  

	14.8	 Recovery. If Epinomics sues under Section 14.6, then any recovery in excess of any unrecovered
litigation costs and fees will be shared with Stanford as follows: 

  

	 	(A)	 any payment for past sales will be deemed Net Sales, and Epinomics will pay Stanford royalties at the rates
specified in Section 7.8; 

  

	 	(B)	 any payment for future sales will be deemed a payment under a Sublicense, and royalties will be shared as
specified in Section 4.6; and 

  

	 	(C)	 Epinomics and Stanford will negotiate in good faith appropriate compensation to Stanford for any non-cash settlement or non-cash cross-license. 

  

	14.9	 Abandonment of Suit. If either Stanford or Epinomics commences a suit and thereafter elects to abandon
the suit, it will give timely notice to the other party. The other party may continue prosecution of the suit after Stanford and Epinomics agree on the sharing of expenses and any recovery in the suit. 

 

	15.	 TERMINATION 

  

	15.1	 Termination by Epinomics. 

 

	 	(A)	 Epinomics may terminate this Agreement by giving Stanford written notice at least 30 days in advance of the
effective date of termination selected by Epinomics. 

  

	 	(B)	 Epinomics may terminate this Agreement as to any particular patent application or patent within the Licensed
Patents by giving Stanford written notice at least 30 days in advance of the effective date of termination selected by Epinomics. From and after the effective date of a termination under this Section 15.1 with respect to a particular patent
application or patent, such patent application or patent in the particular country shall cease to be within the Licensed Patents for purposes of this Agreement. 

 

	15.2	 Termination by Stanford. 

 

	 	(A)	 Stanford may also terminate this Agreement on thirty (30) days written notice if Epinomics:

  

	 	(1)	 is in material default in the provision of any report or payment of amounts due; 

 

	 	(2)	 is not using commercially reasonably efforts in developing and commercializing Licensed Product;

  
  

PAGE 20 OF 28 

	 	(3)	 misses a milestone described in Appendix A, subject to Epinomics’s right to extend the timeline for
milestones pursuant to Section 6.1, and further subject to the specific remedies in Section 6.1 for failure to meet Milestone 6 in Appendix A; 

  

	 	(4)	 is in material breach of any provision; or 

 

	 	(5)	 provides any materially false report. 

 

	 	(B)	 Termination under this Section 15.2 will take effect 30 days after written notice by Stanford unless
Epinomics remedies the specified default or breach in that 30-day period. 

  

	15.3	 Surviving Provisions. Surviving any termination or expiration are: 

 

	 	(A)	 Epinomics’s obligation to pay royalties accrued or accruable; 

 

	 	(B)	 any claim of Epinomics or Stanford, accrued or to accrue, because of any breach or default by the other party;
and 

  

	 	(C)	 the provisions of Articles 8, 9, and 10, 11, 12, 13, 17, 18, 19, 20, and Sections 15.3, and any other provision
that by its nature is intended to survive; and 

  

	 	(D)	 any Sublicense granted hereunder, provided that the Sublicensee agrees in writing to be bound by the applicable
terms of this Agreement. 

  

	16.	 CHANGE OF CONTROL AND NON-ASSIGNABILITY 

 

	16.1	 Change of Control. If there is a Change of Control, Epinomics will pay Stanford [***] (“Change of
Control Fee”) upon assignment of this Agreement per Section 16.2. 

  

	16.2	 Conditions of Assignment under Change of Control. Epinomics may assign this Agreement as part of a
Change of Control upon prior and complete performance of the following conditions: 

  

	 	(A)	 Epinomics must give Stanford 15 days prior written notice of the assignment, including the new assignee’s
contact information; and 

  

	 	(B)	 the new assignee must agree in writing to Stanford to be bound by this Agreement; and 

 

	 	(C)	 Stanford must have received the full Change of Control Fee, provided that such fee shall be due for the
first Change of Control under this Agreement only. 

  

	16.3	 After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 16, Epinomics
will be released of liability under this Agreement and the term “Epinomics” in this Agreement will mean the assignee. 

  
  

PAGE 21 OF 28 

	16.4	 Bankruptcy. In the event of a bankruptcy, assignment is permitted only to a party that can provide
adequate assurance of future performance, including diligent development and sales, of Licensed Product. 

  

	16.5	 Nonassignability of Agreement. Except in conformity with Sections 16.2 and 16.4, this Agreement is not
assignable by Epinomics under any other circumstances and any attempt to assign this Agreement by Epinomics is null and void. 

  

	17.	 DISPUTE RESOLUTION 

 

	17.1	 Dispute Resolution by Arbitration. Any dispute between the parties regarding any payments made or due
(including for Nonroyalty Sublicensing Consideration) under this Agreement, will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures. The parties are not obligated to settle any other dispute that may arise under
this Agreement by arbitration. Notwithstanding the foregoing, no dispute affecting the rights or property of HHMI shall be subject to the arbitration provisions set forth in this Article 17. 

 

	17.2	 Request for Arbitration. Either party may request such arbitration. Stanford and Epinomics will mutually
agree in writing on a third party arbitrator selected according to the JAMS Arbitration Rules and Procedures or mutually agreed upon in writing by Stanford and Epinomics within 30 days of the arbitration request. The arbitrator’s decision will
be final and nonappealable and may be entered in any court having jurisdiction. 

  

	17.3	 Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the
California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery according to the JAMS Arbitration Rules and Procedures. 

  

	17.4	 Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually
agree in writing to another place. 

  

	17.5	 Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the
courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. 

  

	18.	 NOTICES 

  

	18.1	 Legal Action. Epinomics will provide written notice to Stanford at least three months prior to bringing
an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. Epinomics will include with such written notice an identification of all prior art it believes invalidates any claim of
the Licensed Patent. 

  
  

PAGE 22 OF 28 

	18.2	 All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent
as follows: 

 All general notices to Epinomics are mailed or emailed to: 

EPINOMICS 
 1430 O’Brien Dr,
Ste D-1 
 Menlo Park, CA 94025 

epi@Epinomics.co 
 All financial
invoices to Epinomics (i.e., accounting contact) are e-mailed to: 
 EPINOMICS 

epi@Epinomics.co 
 (cc:
fin@Epinomics.co) 
 All progress report invoices to Epinomics (i.e., technical contact) are e-mailed
to: 
 EPINOMICS 

epi@Epinomics.co 
 (cc:
fin@Epinomics.co) 
 All general notices to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 
 All
payments to Stanford are mailed to: 
 Stanford University 

Office of Technology Licensing 

Department #44439 
 P.O. Box 44000

 San Francisco, CA 94144-4439 

All progress reports to Stanford are e-mailed or mailed to: 

Office of Technology Licensing 

3000 El Camino Real 
 Building 5,
Suite 300 
 Palo Alto, CA 94306-2100 

info@otlmail.stanford.edu 
 Either
party may change its address with written notice to the other party. 

  
  

PAGE 23 OF 28 

	19.	 CONFIDENTIALITY 

 

	19.1	 Stanford shall maintain the reports and information provided to Stanford pursuant Sections 4.5 (copy of
Sublicense and Sublicense royalty reports), 6.2 (progress reports), 8.1 (earned royalty report), 8.3 (termination report), 8.5 (audit by Stanford) and 8.7 (self audit) of this Agreement in confidence and will not disclose any of the foregoing to any
third party, except as required by law, and shall not use such information except in accordance with the terms of this Agreement and for Stanford’s internal reporting purposes. Stanford’s obligation of confidentiality hereunder shall be
fulfilled by using at least the same degree of care with Epinomics’s confidential information as it uses to protect its other confidential information. Stanford is permitted to share such reports and information with HHMI.

  

	19.2	 Any obligation set forth in the preceding paragraph shall not apply to any information, knowledge, and/or know-how which: 

  

	 	(A)	 Is or hereafter becomes a part of the public knowledge through no fault of Stanford; 

 

	 	(B)	 Stanford can demonstrate was in its rightful possession prior to the time of disclosure by Epinomics; and

  

	 	(C)	 Stanford can demonstrate was received by it from a third party who did not receive the same from Epinomics.

  

	20.	 MISCELLANEOUS 

 

	20.1	 Waiver. No term of this Agreement can be waived except by the written consent of the party waiving
compliance. 

  

	20.2	 Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of
California, United States of America, applicable to agreements negotiated, executed, and performed within California. 

  

	20.3	 Entire Agreement. The parties have read this Agreement and agree to be bound by its terms, and further
agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof. This Agreement may
not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party. 

 

	20.4	 Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United
States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. Epinomics submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Epinomics or
constitutes an inconvenient or improper forum. 

  

	20.5	 Third Party Beneficiary. HHMI is not a party to this Agreement and has no liability to any licensee,
sublicensee, or user of anything covered by this Agreement, but HHMI is an intended third-party beneficiary of this Agreement and certain of its provisions are for the benefit of HHMI and are enforceable by HHMI in its own name.

  

	20.6	 Headings. No headings in this Agreement affect its interpretation. 

  
  

PAGE 24 OF 28 

	20.7	 Electronic Copy. The parties to this document agree that a copy of the original signature (including an
electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the
absence of an original signature. 

 The parties execute this Agreement in duplicate originals by their duly authorized officers or
representatives. 
  

			
	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
		
	Signature:	 	 /s/ Katharine Ku

	Name:	 	Katharine Ku
	Title:	 	Executive Director, Technology Licensing
	Date:	 	November 4, 2015

  

			
	EPINOMICS
		
	Signature:	 	 /s/ Paul Giresi

	Name:	 	Paul Giresi
	Title:	 	Officer
	Date:	 	November 4, 2015

  
  

PAGE 25 OF 28 

 Appendix A—Milestones 

[***] 

  
  

PAGE 26 OF 28 

 Appendix B—Sample Reporting Form 

Stanford Docket No. S        — 

This report is provided pursuant to the license agreement between Stanford University and (Company Name) 

License Agreement Effective Date: 
 Name(s) of Licensed Products
being reported: 
  

					
	 Report Covering Period
	  			
	 Yearly Maintenance Fee
	  	$	             	 
	 Number of Sublicenses Executed
	  			
	 Gross Revenue
	  			
	 U.S. Gross Revenue
	  	$	 	 
	 Non-U. S. Gross Revenue
	  	$	 	 
	 Net Sales
	  			
	 U.S. Net Sales
	  	$	 	 
	 Non-U. S. Net Sales
	  	$	 	 
	 Royalty Calculation
	  			
	 Royalty Subtotal
	  	$	 	 
	 Credit
	  	$	 	 
	 Royalty Due
	  	$	 	 

 Comments: 

  
  

PAGE 27 OF 28 

 Appendix C—Letter Stating Value of Shares 

1430 O’Brien Drive, Suite D-l 

Menlo Park, CA 94025 
 <insert Effective Date of License
Agreement> 
 Ms. Katharine Ku 
 Executive Director,
Office of Technology Licensing 
 3000 El Camino Real, Building 5, Suite 300 

Palo Alto, CA 94306 
 Dear Ms. Ku: 

As of effective date of the license agreement, the Epinomics Board of Directors determined the fair market value of the common stock of Epinomics to be
$             per share. 
 Sincerely, 

<Name> 
 <Title> 

  
  

PAGE 28 OF 28

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]